secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001654954-24-010454
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics reports Q2 net loss of $3.6M, cash $9.4M; raised $100M
-------------------------------------------------------------------------

- Net loss of $3.6M ($1.83/sh) vs loss of $1.1M ($4.00/sh) in Q2 2023.
- R&D expenses $2.3M, up from $0.2M due to Phase 3 LEVEL study costs.
- Cash and equivalents $9.4M at June 30; subsequent private placement raised $100M gross.
- Phase 3 LEVEL study enrolling with 39 investigative sites; patent granted for levosimendan in PH-HFpEF.
- G&A expenses $1.3M vs $1.0M in prior-year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424010454/0001654954-24-010454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424010454/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-010454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer